Indietro

Selezionare la regione

Azienda

Richiedi un consulto sulle cellule staminali

Per saperne di più

I nostri
trapianti

Elenco degli utilizzi delle cellule staminali approvati dai laboratori del gruppo FamiCord:

Immagine
Elenco degli utilizzi delle cellule staminali approvati dai laboratori del gruppo FamiCord:
Nr. Fonte Tipo di fonte Diagnosi Settore medico Anno di applicazione Terapia Paese Età del destinatario
1001 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2025 Standard Therapy USA 39
1002 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 45
1003 Apheresis Autologous Acute myeloid leukemia Hematology 2025 Standard Therapy Germany 59
1004 Apheresis Allogeneic Multiple myeloma Hematology 2025 Standard Therapy Germany 68
1005 Apheresis Allogeneic Multiple myeloma Hematology 2025 Standard Therapy Germany 68
1006 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 73
1007 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 66
1008 Apheresis Autologous Acute myeloid leukemia Hematology 2025 Standard Therapy Germany 69
1009 Apheresis Autologous Hodgkin lymphoma Hematology 2025 Standard Therapy Germany 38
1010 Apheresis Allogeneic Tcell acute leukemia Hematology 2025 Standard Therapy Romania 31
1011 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Italy 37
1012 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Sweden 69
1013 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 55
1014 Apheresis Allogeneic Fanconi's Anemia Hematology 2025 Standard Therapy Russia 14
1015 Apheresis Allogeneic Peripheral T-cell Lymphoma not otherwise specified Hematology 2025 Standard Therapy Germany 54
1016 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy France 63
1017 Apheresis Allogeneic Myeloid Sarcoma Hematology 2025 Standard Therapy Poland 48
1018 Apheresis Allogeneic Other Myelofibrosis/Myelosclerosis Hematology 2025 Standard Therapy USA 72
1019 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2025 Standard Therapy Germany 11
1020 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 37
1021 Apheresis Allogeneic Myelofibrosis Hematology 2025 Standard Therapy Australia 59
1022 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 35
1023 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Poland 51
1024 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 59
1025 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Poland 70
1026 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy USA 70
1027 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 66
1028 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 63
1029 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 66
1030 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Italy 61
1031 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 71
1032 Apheresis Allogeneic Chronic Lymphocytic Leukemia Hematology 2025 Standard Therapy Czechia 45
1033 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Brazil 61
1034 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Hungary 35
1035 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy NETHERLANDS 48
1036 Apheresis Allogeneic Mantle Cell Lymphoma Hematology 2025 Standard Therapy Ireland 62
1037 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Poland 62
1038 Apheresis Allogeneic Acute Myeloid Leukemia, Myelodysplasia-Related Hematology 2025 Standard Therapy Russia 53
1039 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 56
1040 Apheresis Allogeneic Myelofibrosis Myeloid Metaplasia Hematology 2025 Standard Therapy USA 68
1041 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 70
1042 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 62
1043 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 53
1044 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 52
1045 Apheresis Autologous Diffuse large B-cell lymphoma Hematology 2025 Standard Therapy Germany 63
1046 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 72
1047 Apheresis Autologous Central nervous system lymphoma Hematology 2025 Standard Therapy Germany 64
1048 Apheresis Allogeneic Acute myeloid leukemia Hematology 2025 Standard Therapy Germany 74
1049 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Germany 65
1050 Apheresis Allogeneic T-cell prolymphocytic leukemia Hematology 2025 Standard Therapy Germany 53
1051 Apheresis Autologous Central nervous system lymphoma Hematology 2025 Standard Therapy Germany 70
1052 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 61
1053 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 54
1054 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 41
1055 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 32
1056 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 72
1057 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2025 Standard Therapy Poland 52
1058 Apheresis Allogeneic Chronic Myeloid Leukemia Hematology 2025 Standard Therapy Poland 50
1059 Apheresis Allogeneic T-cell Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Poland 17
1060 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Poland 66
1061 Apheresis Allogeneic Multiple Myeloma Hematology 2025 Standard Therapy Poland 49
1062 Apheresis Allogeneic Chronic Granulomatous Disease Hematology 2025 Standard Therapy Poland 5
1063 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Poland 55
1064 Apheresis Allogeneic Diffuse Large B-cell Lymphoma Hematology 2025 Standard Therapy Poland 68
1065 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Poland 64
1066 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 51
1067 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 58
1068 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Poland 65
1069 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Poland 61
1070 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2025 Standard Therapy Poland 65
1071 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2025 Standard Therapy Poland 19
1072 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 65
1073 Apheresis Allogeneic Mixed Phenotype Acute Leukemia Hematology 2025 Standard Therapy Poland 47
1074 Apheresis Allogeneic Polycythemia Vera Hematology 2025 Standard Therapy Poland 61
1075 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Poland 56
1076 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 53
1077 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Poland 55
1078 Apheresis Allogeneic Myelodysplastic Syndrome, Myeloproliferative Neoplasms Hematology 2025 Standard Therapy Poland 34
1079 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Poland 50
1080 Apheresis Allogeneic Myelodysplastic Disorders Hematology 2025 Standard Therapy Poland 71
1081 Apheresis Allogeneic Myelofibrosis Myeloid Metaplasia Hematology 2025 Standard Therapy Poland 64
1082 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2025 Standard Therapy Poland 54
1083 Apheresis Autologous Non-Hodgkin lymphoma Hematology 2025 Standard Therapy Germany 50
1084 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 50
1085 Apheresis Allogeneic Acute myeloid leukemia Hematology 2025 Standard Therapy Germany 35
1086 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 54
1087 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 52
1088 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 61
1089 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 55
1090 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 64
1091 Apheresis Autologous Central Nervous System Lymphoma Hematology 2025 Standard Therapy Germany 68
1092 Apheresis Allogeneic Primary myelofibrosis Hematology 2025 Standard Therapy Germany 71
1093 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 47
1094 Apheresis Autologous Central Nervous System Lymphoma Hematology 2025 Standard Therapy Germany 58
1095 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 68
1096 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Portugal 44
1097 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Portugal 59
1098 Apheresis Autologous Lymphoma Non-Hodgkin Hematology 2025 Standard Therapy Portugal 58
1099 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Sweden 59
1100 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 2